LIVE
⭐4.7M influencer listings 🏢55.1K sponsor listings 🌍72.6B combined audience reach 📊13 platforms indexed 🗺️130+ countries covered 🏷️10,000+ niches 🦋2M Bluesky creators 🎙️1.2M podcast creators 🟣838.1K Twitch creators 🐘162.4K Mastodon creators 🥊115.3K Kick creators 📈103.4K Pinterest creators 𝕏95.5K X creators ▶️87.5K YouTube creators ✈️59.6K Telegram creators 🎵41.2K TikTok creators 🎮8.7K Discord creators 🎬4.3K Rumble creators 📈2.4K Substack creators 🧵1.7K Threads creators ⭐4.7M influencer listings 🏢55.1K sponsor listings 🌍72.6B combined audience reach 📊13 platforms indexed 🗺️130+ countries covered 🏷️10,000+ niches 🦋2M Bluesky creators 🎙️1.2M podcast creators 🟣838.1K Twitch creators 🐘162.4K Mastodon creators 🥊115.3K Kick creators 📈103.4K Pinterest creators 𝕏95.5K X creators ▶️87.5K YouTube creators ✈️59.6K Telegram creators 🎵41.2K TikTok creators 🎮8.7K Discord creators 🎬4.3K Rumble creators 📈2.4K Substack creators 🧵1.7K Threads creators
Sanofi

Sanofi

X @sanofi
⚔ Compare ☆ Follow Own this channel?
🔄 Data last refreshed 14 hours ago
🤝

Make a deal with Sanofi

🔒 Paid proposals held safely in escrow — released only when the work's approved.

📣Sponsored postOne tweet with your link and creative. $1,165→ 🧵Sponsored threadA multi-tweet thread — X rewards long-form, threads out-reac… $2,913→ 🎬Sponsored video postA dedicated video tweet — X pushes video hard, so it gets pr… $1,631→ 📌Pinned postA sponsored post pinned to the top of my profile for the mon… $3,495/mo→ 📍Post + pin comboA sponsored post that also stays pinned for a set number of … $1,864→ 🔁Repost / quote-tweet packageI repost or quote-tweet your posts through the month — distr… $2,330/mo→ 🔗Bio link placementYour link in my bio for the month — X allows only one, so it… $1,748/mo→ 🎙️X Spaces appearance / hostI host or feature you in an X Space (live audio) — a branded… $2,330→ 🤝Cross-promo / mutual shoutoutWe shout each other out — a value swap between accounts. Swap→ 🎬UGC HireBranded content for your own channels & ads from $510→ 🎙️Podcast guest spotInvite Sanofi onto your podcast (~45 min, remote) $510→ 📞1:1 ConsultPaid video call — advice, coaching or Q&A $82/hr→

Every booking is a normal escrow-protected deal.

Followers
145.7K
Posts
7.4K
Following
215
Account age
17 yrs
🎁 Free analysisfor Sanofi
🕵️Fake Followers CheckReal-audience % & bot risk→ 📊Engagement rateBenchmarked vs. peers→ 💰What they chargeFair sponsored-post price→

Known for

#NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: https://t.co/VOyUtc3ax4 3.5K views #NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: https://t.co/VOyUtc3ax4 Our Q2 2026 results are now available. Read the full press release for detailed insights: https://t.co/ZijzaqKgmQ #SanofiResults $SAN $SNY 2.4K views Our Q2 2026 results are now available. Read the full press release for detailed insights: https://t.co/ZijzaqKgmQ #SanofiResults $SAN $SNY #NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ https://t.co/cZ6YH5IPhM 2.2K views #NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ https://t.co/cZ6YH5IPhM Our Q1 2026 results are now available. See the press release for more details: https://t.co/McL3v5nR1p #SanofiResults $SAN $SNY 2.1K views Our Q1 2026 results are now available. See the press release for more details: https://t.co/McL3v5nR1p #SanofiResults $SAN $SNY

📊 Post performance

1.7K
Avg views / post
1.2%
Reach vs followers
Apr 2009
On X since

🔥 Top post: #NEWS: Our phase 3 results show our medicine met its primary and · 3.5K views

📊 Activity & format

Posting cadence
1.2 / week
A lower-frequency account — each post lands with more weight.
Content mix
Mostly images
Recent: 2 video · 15 image · 0 text.
Follower / following
678×
Follows 215 back. A strong ratio — an audience that follows them, not a follow-for-follow network.

Recent posts

View on X ↗
🔥 Top post #NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: https://t.co/VOyUtc3ax4 3.5K❤ 13🔁 5
Our Q2 2026 results are now available. Read the full press release for detailed insights: https://t.co/ZijzaqKgmQ #SanofiResults $SAN $SNY 2.4K❤ 13🔁 12 #NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ https://t.co/Pp1lF0swiy 1.9K❤ 5🔁 4 #NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: https://t.co/gynO8BFmZi 2K❤ 9🔁 6 #NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn … 2.2K❤ 14🔁 4 Sanofi appoints Paulo Fontoura as Global Head of R&D Pharma, starting September 1, 2026. With 25+ years in pharmaceutical innovation, he brings a track record of 60+ new molecular entities and 20+ FDA/EMA approvals. Read more: https:… 1.5K❤ 8🔁 5 ▶ We're chasing the miracles of science to improve people's lives. Last week, the world saw exactly how. 2026 marked our 8th consecutive year at #VivaTech, and we came to show, not tell, with operational AI delivering real impact for patie… 2K❤ 11🔁 4 The Ministry of Health, Labour and Welfare in Japan has approved our subcutaneous therapy in combination with approved standard-of-care regimens for the treatment of multiple myeloma. Read the full announcement here: https://t.co/y8bEfZ6Wt… 1.7K❤ 13🔁 5 ▶ What a start at #VivaTech! Visit us at Booth 1D01 through June 20 to experience how we’re reinventing AI across the value chain. Learn more: https://t.co/ufbsOfGFA1 #Sanofi @VivaTech 849❤ 5🔁 2 We’re back at #VivaTech 2026, and we’re raising the bar on what AI can do for global health. Visit us June 17 – 20 at Booth 1D01 to see how our teams are accelerating breakthroughs across everything from research and development to manuf… 939❤ 6🔁 2 The @US_FDA granted accelerated approval for a treatment for #Type1Diabetes. Learn more: https://t.co/T7dMsW67eA 1.2K❤ 15🔁 2 #NEWS: Update on our phase 3 clinical study in chronic inflammatory demyelinating polyneuropathy (CIDP). Learn more ⬇️ https://t.co/G12CzYjKyz 1.1K❤ 3🔁 3

💡 Facts

🗓️Joined X in 2009 — 17 years ago.
👁️Averages 1.7K views per post.
📤Posts about 1.2× per week.
💬0.01% engagement rate.
🏅Earned the 100K Followers for passing 100K followers.

🕵️ Fake follower check

Estimated
37/100
Low Credibility score
66%
Mixed Real audience
Medium Fake-follower risk
High Data confidence
  • Est. 66% real, active audience · Medium fake-follower risk.
  • Low engagement (~1.2% of followers engage each post) — a sign of an inflated or inactive audience.
  • Organic base — far more followers than accounts it follows.
  • Established account (17+ years old).
  • 0.01% engagement — below the ~14.4% typical for this size.

Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.

About

An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: http://bit.ly/sanofi-terms

📸 Gallery

Our Q2 2026 results are now available. Read the full press release for detailed insights: https://t.co/ZijzaqKgmQ #SanofiResults $SAN $SNY #NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ https://t.co/Pp1lF0swiy #NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: https://t.co/VOyUtc3ax4 #NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: https://t.co/gynO8BFmZi #NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ https://t.co/cZ6YH5IPhM Sanofi appoints Paulo Fontoura as Global Head of R&D Pharma, starting September 1, 2026. With 25+ years in pharmaceutical innovation, he brings a track record of 60+ new molecular entities and 20+ FDA/EMA approvals. Read more: https://t.co/w9T4YIhoJp #Sanofi We're chasing the miracles of science to improve people's lives. Last week, the world saw exactly how. 2026 marked our 8th consecutive year at #VivaTech, and we came to show, not tell, with operational AI delivering real impact for patients, today. Learn more: The Ministry of Health, Labour and Welfare in Japan has approved our subcutaneous therapy in combination with approved standard-of-care regimens for the treatment of multiple myeloma. Read the full announcement here: https://t.co/y8bEfZ6WtI

🔀 Audience overlap

Estimated

Estimated shared audience with similar creators — useful for avoiding overlap (or doubling down) when planning a campaign.

Mahindra Group Mahindra Group 17% Senator Mike Crapo Senator Mike Crapo 17% ( ̂l _ l ̂).̥oͦO̊ ( ̂l _ l ̂).̥oͦO̊ 17% タクヲ タクヲ 16% UNICEF en RDC UNICEF en RDC 15% ベリル🌟Live2Dご依頼受付中！ ベリル🌟Live2Dご依頼受付中！ 12%

More like this

Find more →
X ＋
Mahindra Group
Mahindra Group ✓
@mahindrarise
1.3M Followers
X ＋
ベリル🌟Live2Dご依頼受付中！
ベリル🌟Live2Dご依頼受付中！ ✓
@beriru_illust
701 Followers
X ＋
タクヲ
タクヲ
@taxo876
917 Followers
X ＋
Senator Mike Crapo
Senator Mike Crapo ✓
@mikecrapo
139.5K Followers
X ＋
UNICEF en RDC
UNICEF en RDC
@unicefdrc
191.9K Followers
X ＋
( ̂l _ l ̂).̥oͦO̊
( ̂l _ l ̂).̥oͦO̊
@vl_lvoo
494 Followers

Frequently asked questions

How much does Sanofi charge for a sponsorship?
Sanofi hasn't published fixed prices yet. Send a proposal through SocialDB and agree terms directly — your payment is held in escrow until the work is approved.
How do I contact Sanofi for a brand deal or collaboration?
Send a paid deal or collab request right here on SocialDB — we notify Sanofi, and once they accept, your payment is held safely in escrow and released when the work is approved. You don't need to track down an email.
How many followers does Sanofi have?
Sanofi has 145,663 followers on X.

✉ Message Sanofi

Reaching out to influencers is a Pro feature. Upgrade to message any influencer directly — perfect for brands and agencies booking sponsorships.

  • ✓ Message any influencer from their listing
  • ✓ The influencer gets notified by email
  • ✓ Manage every conversation in one inbox
See Pro $9.95/mo →

Already Pro? Log in.

🎤 Event / appearance with Sanofi

Booking an event / appearance is a Pro feature. Upgrade to book Sanofi for an in-person or virtual appearance — payment held safely in escrow until the event is done.

  • ✓ Book them for events, livestreams, panels & more
  • ✓ Sanofi gets notified by email
  • ✓ Fee held in escrow, released after the appearance
See Pro $9.95/mo →

Already Pro? Log in.

Auto-generated from X's public data — no affiliation with or endorsement by SocialDB. Is this you? Claim it · Remove